Engineered Wnt ligand restores BBB; plus Codiak, Autotac and more
BioCentury’s roundup of translational news
Free University of Brussels researchers, including NeuVasQ Biotechnologies founder Benoit Vanhollebeke, designed a genetically engineered WNT7A ligand and showed in Science that delivering it via an adeno-associated virus (AAV) vector protected blood-brain barrier function in mouse models of glioblastoma and ischemic stroke.
NeuVasQ raised €20 million in series A financing in June led by Newton Biocapital to develop therapies that restore the integrity of the blood-brain barrier to treat neurological disorders...